Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Microsulis launches MEA system

This article was originally published in The Gray Sheet

Executive Summary

U.S. commercial use of minimally invasive microwave endometrial ablation device for uterine lining ablation commences Oct. 6 following PMA approval Sept. 23. Microsulis is training physicians on the device, as was recommended in a June FDA approval condition (1"The Gray Sheet" June 16, 2003, p. 28)...

You may also be interested in...



Financings In Brief

Microsulis: Firm will use $45 mil. round financing to hire 50 direct sales reps/physician educators to support full launch of Microwave Endometrial Ablation (MEA) system to treat menorrhagia. Approved last September, MEA has been slowly rolled out, awaiting funding for clinical specialists required under FDA clearance (1"The Gray Sheet" Oct. 20, 2003, In Brief). Microsulis currently is evaluating distributors for metropolitan areas. The funds also will go to support separate 510(k) applications for soft tissue ablation and peripheral vascular indications to be submitted by year-end. Existing investors contributed $20 mil. to the round, while the remaining $25 mil. came from venture capital...

Microsulis MEA System Labeling Changes Gain OB-GYN Panel’s Support

Users of the Microsulis MEA microwave endometrial ablation system should be trained by experienced physicians, FDA's Obstetrics & Gynecology Devices Panel recommended June 10

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel